We’re excited to attend Nordic Life Science Days from September 8th - 9th in Kista, Sweden. Come meet our experts and join us in learning about the emerging developments across the global life science landscape. This is a valuable opportunity to gain new insights and build strategic partnerships, we look forward to connecting with you.
What is Nordic Life Science Days?
Nordic Life Science (NLS) Days is a largest and fastest growing Nordic partnering event that brings together global life science leaders to explore the latest trends shaping the future of the industry. The program will cover everything from the latest breakthroughs in central nervous system (CNS) research and the impact of AI, to investment opportunities across healthtech.
Event Overview
Date: September 8th - 9th, 2026
Venue: Kistamässan, Arne Beurlings Torg 5, 164 40 Kista, Sweden
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
